TrialJAMA dermatology2017

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Daniel J Lewis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.